Incannex Healthcare (IXHL) Change in Accured Expenses (2023 - 2026)
Incannex Healthcare (IXHL) posted quarterly Change in Accured Expenses of $458000.0 for Q1 2026, down 68.44% year-on-year from $1.5 million in Q1 2025, and up 940.91% on a QoQ basis from $44000.0 in Q4 2025.
Incannex Healthcare (IXHL) Change in Accured Expenses (2023 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Change in Accured Expenses for 4 consecutive years, with $458000.0 the latest figure, recorded in Q1 2026.
- Quarterly Change in Accured Expenses fell 68.44% year-over-year to $458000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (down 223.79% YoY) and the FY2025 annual result came in at $1.4 million, down 54.18% from the prior year.
- Change in Accured Expenses grew to $458000.0 in Q1 2026 per IXHL's latest filing, from $44000.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for IXHL reached as high as $3.3 million in Q3 2024 and fell as low as -$5.4 million in Q3 2025.
- A 4-year average of -$44181.8 and a median of $458000.0 in 2026 frame the typical range for Change in Accured Expenses.
- The largest YoY upside for Change in Accured Expenses was 955.04% in 2024 against a maximum downside of 567.79% in 2024.
- Year by year, Change in Accured Expenses stood at $891000.0 in 2023, then tumbled by 567.79% to -$4.2 million in 2024, then jumped by 101.06% to $44000.0 in 2025, then jumped by 940.91% to $458000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $458000.0, $44000.0, and -$5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn | - |
| 10 | Incannex Healthcare | 37.17 Mn | 37.17 Mn | - | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 458,000.00 |
| Mar 31, 2026 | 458,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Sep 30, 2025 | -5.40 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | 793,000.00 |
| Jun 30, 2025 | 793,000.00 |
| Mar 31, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | -4.17 Mn |
| Dec 31, 2024 | -4.17 Mn |
| Sep 30, 2024 | 3.31 Mn |
| Sep 30, 2024 | 3.31 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Mar 31, 2024 | -202,000.00 |
| Mar 31, 2024 | -202,000.00 |
| Dec 31, 2023 | 891,000.00 |
| Dec 31, 2023 | 891,000.00 |